Helena Teede renames Pcos as PMOS in Prague

Helena Teede announced today at the European Congress of Endocrinology in Prague, Czech Republic, that pcos will now be known as polyendocrine metabolic ovarian syndrome, or PMOS. The name change is meant to correct the idea that the ovaries are the only part of the body affected.

Alice Klein, who was diagnosed more than two decades ago in her late teens, said of the official rename: “it’s been a long time coming.” She first wrote about the condition for New Scientist in 2018.

Prague announcement

Teede’s announcement puts a formal name on a problem that the old term never captured well. The condition has long been called polycystic ovary syndrome, even though the source says the dark spots seen on ultrasound are not cysts at all. Those spots are eggs that have been unable to mature fully and be released via ovulation.

The new name, PMOS, shortens to a label that still signals the ovarian link while adding the metabolic and endocrine features that shape the condition. The source says the condition is characterized by high levels of male sex hormones like testosterone and that insulin resistance is common.

What PMOS covers

PCOS can cause acne, excess hair on the face and body, thinning hair on the head, weight gain, irregular or absent periods, type 2 diabetes, high blood pressure and heart disease. It can also make it take longer to become pregnant because eggs are released less often for potential fertilisation.

The source says about 80 per cent of women with the condition conceive without medication or IVF, and women with the condition are just as likely to ultimately have their desired family size as those without it. That leaves a sharper practical message for readers: the diagnosis is broader than fertility, and the renamed condition is intended to reflect that broader picture.

A name with medical weight

Klein’s own timeline captures why the change landed now. She was diagnosed in her late teens more than two decades ago, then later wrote publicly about the condition in 2018. Teede’s announcement in Prague brings the language used by clinicians closer to the way the condition has been described in the research and in patients’ lives.

For people living with pcos, the immediate change is the name itself: PMOS is now the term attached to the condition. The next step is simpler than the old label suggested — any discussion with a clinician now starts from the fact that the syndrome involves more than the ovaries, and that the symptoms can reach across hormones, metabolism and fertility.